广康生化及董事长财务总监收警示函 2023上市募7.85亿

Core Viewpoint - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Bureau due to violations related to the management and use of raised funds, specifically regarding the purchase of non-principal guaranteed financial products without adequate risk disclosure [1][2]. Group 1: Regulatory Actions - The Guangdong Securities Regulatory Bureau issued a warning letter to Guangkang Biochemical and its executives, Cai Danqun and Chen Haixia, for failing to fulfill their responsibilities under the Information Disclosure Management Measures [2]. - The company was found to have used raised funds to purchase 179 financial products, of which 158 were non-principal guaranteed, without sufficient disclosure of the associated risks in their reports [1][2]. Group 2: Financial Details - Guangkang Biochemical was listed on the Shenzhen Stock Exchange's ChiNext on June 27, 2023, issuing 18.5 million shares at a price of 42.45 yuan per share, which currently trades below its initial offering price [2]. - The total amount raised by the company was 785.325 million yuan, with a net amount of 697.3657 million yuan after deducting issuance costs, which exceeded the initially planned amount by 6.1779 million yuan [2].